Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology
Gelteq (NASDAQ: GELS) has appointed Dr. Paul Wynne as its new Chief Scientific Officer (CSO). Dr. Wynne brings over 35 years of experience in analytical chemistry, advanced materials, drug metabolism, pharmaceutical formulation, and drug delivery. Prior to joining Gelteq, he served as Manager of the Medicines Manufacturing Innovation Centre at Monash University for eight years.
In his new role, Dr. Wynne will oversee product and formulation strategies, lead the scientific team's growth, manage the company's intellectual property portfolio, and coordinate with manufacturing partners. His expertise includes authoring over 80 peer-reviewed papers and 120 industry presentations. He holds multiple advanced degrees from RMIT University, including a PhD in Chemistry and Toxicology.
Gelteq (NASDAQ: GELS) ha nominato Dr. Paul Wynne nuovo Chief Scientific Officer (CSO). Il Dr. Wynne porta con sé oltre 35 anni di esperienza in chimica analitica, materiali avanzati, metabolismo dei farmaci, formulazione farmaceutica e somministrazione di farmaci. Prima di unirsi a Gelteq, ha ricoperto il ruolo di Manager del Medicines Manufacturing Innovation Centre presso la Monash University per otto anni.
Nel suo nuovo ruolo, il Dr. Wynne supervisionerà le strategie di prodotto e formulazione, guiderà la crescita del team scientifico, gestirà il portafoglio di proprietà intellettuale dell’azienda e coordinerà con i partner di produzione. La sua expertise include la pubblicazione di oltre 80 articoli peer-reviewed e 120 presentazioni nell'industria. Possiede diversi titoli avanzati dall'RMIT University, inclusi un dottorato in Chimica e Tossicologia.
Gelteq (NASDAQ: GELS) ha nombrado al Dr. Paul Wynne como su nuevo Director Científico (CSO). El Dr. Wynne aporta más de 35 años de experiencia en química analítica, materiales avanzados, metabolismo de fármacos, formulación farmacéutica y administración de medicamentos. Antes de unirse a Gelteq, se desempeñó como Gerente del Medicines Manufacturing Innovation Centre en la Universidad de Monash durante ocho años.
En su nuevo cargo, el Dr. Wynne supervisará las estrategias de productos y formulaciones, liderará el crecimiento del equipo científico, gestionará la cartera de propiedad intelectual de la empresa y coordinará con los socios de fabricación. Su experiencia incluye la autoría de más de 80 artículos revisados por pares y 120 presentaciones en la industria. Posee múltiples títulos avanzados de la RMIT University, incluido un doctorado en Química y Toxicología.
Gelteq (NASDAQ: GELS)는 Paul Wynne 박사를 새로운 최고 과학 책임자(CSO)로 임명했습니다. Wynne 박사는 분석 화학, 고급 소재, 약물 대사, 제약 제형 및 약물 전달에 35년 이상의 경험을 가지고 있습니다. Gelteq에 합류하기 전, 그는 Monash University의 의약품 제조 혁신 센터에서 8년 동안 매니저로 근무했습니다.
새로운 역할에서 Wynne 박사는 제품 및 제형 전략을 감독하고, 과학 팀의 성장을 이끌며, 회사의 지적 재산 포트폴리오를 관리하고, 제조 파트너와 조정할 것입니다. 그의 전문 분야에는 80편 이상의 동료 검토 논문과 120편의 산업 발표가 포함됩니다. 그는 RMIT University에서 화학 및 독성학 박사학위를 포함하여 여러 고급 학위를 보유하고 있습니다.
Gelteq (NASDAQ: GELS) a nommé Dr. Paul Wynne comme nouveau Directeur Scientifique (CSO). Dr. Wynne apporte plus de 35 ans d'expérience en chimie analytique, matériaux avancés, métabolisme des médicaments, formulation pharmaceutique et administration des médicaments. Avant de rejoindre Gelteq, il a été directeur du Medicines Manufacturing Innovation Centre à l'Université de Monash pendant huit ans.
Dans son nouveau rôle, Dr. Wynne supervisera les stratégies de produits et de formulation, dirigera la croissance de l'équipe scientifique, gérera le portefeuille de propriété intellectuelle de l'entreprise et coordonnera avec les partenaires de fabrication. Son expertise inclut la rédaction de plus de 80 articles évalués par des pairs et 120 présentations dans l'industrie. Il détient plusieurs diplômes avancés de l'Université RMIT, y compris un doctorat en chimie et toxicologie.
Gelteq (NASDAQ: GELS) hat Dr. Paul Wynne zu seinem neuen Chief Scientific Officer (CSO) ernannt. Dr. Wynne bringt über 35 Jahre Erfahrung in analytischer Chemie, fortschrittlichen Materialien, Arzneimittelstoffwechsel, pharmazeutischer Formulierung und Arzneimittelverabreichung mit. Vor seinem Wechsel zu Gelteq war er acht Jahre lang Manager des Medicines Manufacturing Innovation Centre an der Monash University.
In seiner neuen Rolle wird Dr. Wynne die Produkt- und Formulierungsstrategien überwachen, das Wachstum des wissenschaftlichen Teams leiten, das geistige Eigentum des Unternehmens verwalten und mit den Fertigungspartnern koordinieren. Zu seinen Fachkenntnissen gehören die Verfassung von über 80 begutachteten Artikeln und 120 Branchenpräsentationen. Er hat mehrere fortgeschrittene Abschlüsse von der RMIT University, darunter einen Doktortitel in Chemie und Toxikologie.
- Appointment of highly qualified CSO with 35+ years of relevant industry experience
- New CSO brings extensive academic credentials and research background with 80+ peer-reviewed publications
- Strategic addition to strengthen scientific leadership and product development capabilities
- None.
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the appointment of Dr. Paul Wynne as its Chief Scientific Officer (“CSO”).
Gelteq co-founder and CEO Nathan Givoni stated, “We believe Dr. Wynne’s distinguished record and expertise in formulation science and drug delivery systems will be instrumental in driving the next phase of Gelteq’s product pipeline. Recognized for his collaborative approach and ability to coordinate high-performing teams that drive scientific excellence, Dr. Wynne’s pedigree aligns with Gelteq’s mission to enhance health and wellness through our novel ingestible gel technology. We look forward to further strengthening our senior management team as we continue to execute a strategic plan to build long-term value for all of our stakeholders.”
Dr. Wynne will oversee the product and formulation strategies and the growth of Gelteq’s scientific team and various business verticals. He will assist with Gelteq’s intellectual property portfolio, academic partnerships, gel formulations, and distribution channels, and will work closely with manufacturing and supply side partners.
Dr. Wynne commented, “I am honored to join Gelteq at such an exciting inflection point for the Company and the industry. I look forward to guiding the Company’s efforts to fully harness the potential of our ingestible gel technology across a myriad of market applications to meet the evolving needs of consumers and patients around the world.”
Dr. Wynne has over 35 years of experience in the disciplines of analytical chemistry, the design and manufacture of advanced materials, drug metabolism, pharmaceutical formulation, drug delivery and forensic toxicology. Prior to joining Gelteq, he was the Manager of the Medicines Manufacturing Innovation Centre at Monash University in Melbourne for eight years, which works to strengthen the pharmaceutical and allied manufacturing sector in Australia for domestic and International clients. Monash University is ranked #2 in the world in pharmacy and pharmaceutical science by the QS World University Rankings by Subject 2024: Pharmacy & Pharmacology. Dr. Wynne is also the author of over 80 peer reviewed papers, book chapters, and patents, and more than 120 lectures, presentations and industry technical articles. He holds a Bachelor of Applied Science (Applied Chemistry), Master of Applied Science (Organic Photochemistry), and a Doctor of Philosophy (Chemistry and Toxicology) from RMIT University.
About Gelteq Limited:
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a global biotechnology company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products. Gelteq advances and commercializes its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. The Company’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit www.gelteq.com.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Gelteq’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future orders relating to Gelteq’s products, the success of new programs, the ability to implement a new strategic plan and the success of a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gelteq in general, see the risk factors in the Annual Report on 20-F filed on November 15, 2024. All such forward-looking statements speak only as of the date they are made, and Gelteq undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.
Contact:
CORE IR
516-222-2560
PR@gelteq.com
FAQ
What experience does Dr. Paul Wynne bring to his new CSO role at Gelteq (GELS)?
What will be Dr. Paul Wynne's responsibilities as CSO of Gelteq (GELS)?
What is Dr. Paul Wynne's academic background before joining Gelteq (GELS)?
How many publications and presentations has Dr. Paul Wynne authored before joining Gelteq (GELS)?
